UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents make the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AMGEN/UCB’S OSTEOPOROSIS DRUG HIT BY CARDIO RISK

Amgen | May 24, 2017

news image

Amgen and UCB have suffered a setback to their osteoporosis drug, romosozumab, after first phase 3 trial results revealed a heart safety signal. Evenity, as it will be branded if approved, is under review with the FDA, which had been due to make a decision on the drug in July....

Read More

US REGULATORS TURN AWAY AMGEN/UCB’S BONE DRUG EVENITY

Amgen | July 17, 2017

news image

Amgen and UCB’s application to market bone-boosting drug Evenity as a treatment for postmenopausal women with osteoporosis has hit a setback, having been turned down by US regulators. The US Food and Drug Administration has issued a Complete Response Letter asking for new safety and efficacy data from the Phase III active-comparator ARCH study to be integrated into the drug’s submission, to build on that included in the original filing taken from the Phase III placebo-controlled FRAME study. The...

Read More

SMC APPROVES NHS FUNDING FOR UCB’S VIMPAT IN CHILDREN

PharmaTimes | February 20, 2018

news image

The Scottish Medicines Consortium has accepted Vimpat (lacosamide) for NHS use as an adjunctive therapy for partial-onset (focal) seizures with or without secondary generalisation in children aged four years and older. In Scotland there are around 55,000 people living with epilepsy but, despite its high prevalence, around 10-29 percent of children with the condition experience inadequate seizure control with currently available anti-epileptic drugs....

Read More

NICE OKAYS UCB’S CIMZIA, NIXES ALMIRALL’S ILUMETRI, IN PSORIASIS

Pharmaphorum Media Limited | December 05, 2018

news image

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money. Cimzia (certolizumab pegol) was approved in Europe in the new indication of plaque psoriasis earlier this year, adding to a list of uses including rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. While there are a number of other anti-TNF drugs approved in psoriasis, in...

Read More
news image

AMGEN/UCB’S OSTEOPOROSIS DRUG HIT BY CARDIO RISK

Amgen | May 24, 2017

Amgen and UCB have suffered a setback to their osteoporosis drug, romosozumab, after first phase 3 trial results revealed a heart safety signal. Evenity, as it will be branded if approved, is under review with the FDA, which had been due to make a decision on the drug in July....

Read More
news image

US REGULATORS TURN AWAY AMGEN/UCB’S BONE DRUG EVENITY

Amgen | July 17, 2017

Amgen and UCB’s application to market bone-boosting drug Evenity as a treatment for postmenopausal women with osteoporosis has hit a setback, having been turned down by US regulators. The US Food and Drug Administration has issued a Complete Response Letter asking for new safety and efficacy data from the Phase III active-comparator ARCH study to be integrated into the drug’s submission, to build on that included in the original filing taken from the Phase III placebo-controlled FRAME study. The...

Read More
news image

SMC APPROVES NHS FUNDING FOR UCB’S VIMPAT IN CHILDREN

PharmaTimes | February 20, 2018

The Scottish Medicines Consortium has accepted Vimpat (lacosamide) for NHS use as an adjunctive therapy for partial-onset (focal) seizures with or without secondary generalisation in children aged four years and older. In Scotland there are around 55,000 people living with epilepsy but, despite its high prevalence, around 10-29 percent of children with the condition experience inadequate seizure control with currently available anti-epileptic drugs....

Read More
news image

NICE OKAYS UCB’S CIMZIA, NIXES ALMIRALL’S ILUMETRI, IN PSORIASIS

Pharmaphorum Media Limited | December 05, 2018

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money. Cimzia (certolizumab pegol) was approved in Europe in the new indication of plaque psoriasis earlier this year, adding to a list of uses including rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. While there are a number of other anti-TNF drugs approved in psoriasis, in...

Read More